218 related articles for article (PubMed ID: 15115766)
1. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach.
Hay DG; Sathasivam K; Tobaben S; Stahl B; Marber M; Mestril R; Mahal A; Smith DL; Woodman B; Bates GP
Hum Mol Genet; 2004 Jul; 13(13):1389-405. PubMed ID: 15115766
[TBL] [Abstract][Full Text] [Related]
2. Suppression of protein aggregation by chaperone modification of high molecular weight complexes.
Labbadia J; Novoselov SS; Bett JS; Weiss A; Paganetti P; Bates GP; Cheetham ME
Brain; 2012 Apr; 135(Pt 4):1180-96. PubMed ID: 22396390
[TBL] [Abstract][Full Text] [Related]
3. Novel mechanism of Hsp70 chaperone-mediated prevention of polyglutamine aggregates in a cellular model of huntington disease.
Guzhova IV; Lazarev VF; Kaznacheeva AV; Ippolitova MV; Muronetz VI; Kinev AV; Margulis BA
Hum Mol Genet; 2011 Oct; 20(20):3953-63. PubMed ID: 21775503
[TBL] [Abstract][Full Text] [Related]
4. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
5. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease.
Sittler A; Lurz R; Lueder G; Priller J; Lehrach H; Hayer-Hartl MK; Hartl FU; Wanker EE
Hum Mol Genet; 2001 Jun; 10(12):1307-15. PubMed ID: 11406612
[TBL] [Abstract][Full Text] [Related]
6. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease.
Benn CL; Landles C; Li H; Strand AD; Woodman B; Sathasivam K; Li SH; Ghazi-Noori S; Hockly E; Faruque SM; Cha JH; Sharpe PT; Olson JM; Li XJ; Bates GP
Hum Mol Genet; 2005 Oct; 14(20):3065-78. PubMed ID: 16183657
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine aggregation in Huntington's disease and spinocerebellar ataxia type 3: similar mechanisms in aggregate formation.
Seidel K; Siswanto S; Fredrich M; Bouzrou M; Brunt ER; van Leeuwen FW; Kampinga HH; Korf HW; Rüb U; den Dunnen WF
Neuropathol Appl Neurobiol; 2016 Feb; 42(2):153-66. PubMed ID: 26095752
[TBL] [Abstract][Full Text] [Related]
8. Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggregation. A possible therapeutic strategy.
Herbst M; Wanker EE
Neurodegener Dis; 2007; 4(2-3):254-60. PubMed ID: 17596719
[TBL] [Abstract][Full Text] [Related]
9. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
11. Blind cavefish and heat shock protein chaperones: a novel role for hsp90alpha in lens apoptosis.
Hooven TA; Yamamoto Y; Jeffery WR
Int J Dev Biol; 2004; 48(8-9):731-8. PubMed ID: 15558465
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders.
Reis SD; Pinho BR; Oliveira JMA
Mol Neurobiol; 2017 Oct; 54(8):5829-5854. PubMed ID: 27660272
[TBL] [Abstract][Full Text] [Related]
13. Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lung cancer H460 cells.
Chang YS; Lee LC; Sun FC; Chao CC; Fu HW; Lai YK
J Cell Biochem; 2006 Jan; 97(1):156-65. PubMed ID: 16173045
[TBL] [Abstract][Full Text] [Related]
14. Astrocytic expression of the chaperone DNAJB6 results in non-cell autonomous protection in Huntington's disease.
Bason M; Meister-Broekema M; Alberts N; Dijkers P; Bergink S; Sibon OCM; Kampinga HH
Neurobiol Dis; 2019 Apr; 124():108-117. PubMed ID: 30408590
[TBL] [Abstract][Full Text] [Related]
15. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
Zhang X; Smith DL; Meriin AB; Engemann S; Russel DE; Roark M; Washington SL; Maxwell MM; Marsh JL; Thompson LM; Wanker EE; Young AB; Housman DE; Bates GP; Sherman MY; Kazantsev AG
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):892-7. PubMed ID: 15642944
[TBL] [Abstract][Full Text] [Related]
16. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
[TBL] [Abstract][Full Text] [Related]
17. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1.
Meriin AB; Zhang X; He X; Newnam GP; Chernoff YO; Sherman MY
J Cell Biol; 2002 Jun; 157(6):997-1004. PubMed ID: 12058016
[TBL] [Abstract][Full Text] [Related]
18. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation.
Petrucelli L; Dickson D; Kehoe K; Taylor J; Snyder H; Grover A; De Lucia M; McGowan E; Lewis J; Prihar G; Kim J; Dillmann WH; Browne SE; Hall A; Voellmy R; Tsuboi Y; Dawson TM; Wolozin B; Hardy J; Hutton M
Hum Mol Genet; 2004 Apr; 13(7):703-14. PubMed ID: 14962978
[TBL] [Abstract][Full Text] [Related]
19. Measurement of Chaperone-Mediated Effects on Polyglutamine Protein Aggregation by the Filter Trap Assay.
van Waarde-Verhagen MAWH; Kampinga HH
Methods Mol Biol; 2018; 1709():59-74. PubMed ID: 29177651
[TBL] [Abstract][Full Text] [Related]
20. Cofactor Tpr2 combines two TPR domains and a J domain to regulate the Hsp70/Hsp90 chaperone system.
Brychzy A; Rein T; Winklhofer KF; Hartl FU; Young JC; Obermann WM
EMBO J; 2003 Jul; 22(14):3613-23. PubMed ID: 12853476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
